KDR and renal cell carcinoma: Moreover, since angiogenesis is an important hallmark of RCC, and since different agents included in the initial drug set targeting VEGF/VEGFR axis are in clinical use for RCC [40], we included the angiogenic human cell line EC-RF24 [28] in this screen as well.